Modular Solution for Cosmetics Compliance
Check the Conformity of your Formulas
Secure your regulatory documents for each zone
Optimize on-site risk management
Manage your Safety Data Sheets efficiently
Automate your regulatory monitoring
Ensure the traceability of your substances
Maintain good HSE risk management
ECHA has launched a consultation on the proposed REACH restriction of Octocrylene in cosmetics. Learn what the proposal means for manufacturers, formulators and regulatory teams.
Recevez une fois par mois les dernières actus réglementaires et conseils d’experts.
The European Commission has proposed 5 new substances for inclusion in Annex XIV of the REACH Regulation, subject to authorization. Companies using these substances must find alternatives or submit an authorization dossier.
ECHA added 8 new substances to the Candidate List for authorisation, bringing the total to 219. Learn about the new entries and the obligations that arise when substances are classified as SVHCs.
Learn about your obligations under SCIP if you are a European supplier of articles containing SVHC substances. Find out when to update your SCIP notification and what information to provide. SCIP aims to make information on hazardous substances available to waste managers and consumers for safer product disposal.
Understanding the compliance of medical devices with new regulations can be complex and costly. Companies need to invest time and resources in various aspects such as training, market surveillance, and continuous data collection. Working with a specialist consultant can help navigate these challenges and ensure product compliance. Learn more about the impact of Regulation 2017/745 and the importance of post-marketing surveillance in this blog.
Post-Brexit, the UK established its own biocides regulation, requiring companies to resubmit marketing authorisation and active substance approval dossiers to the Health & Safety Executive. This process involves new forms and data submissions to ensure compliance with the GB BPR.
The NMPA's ban on cannabis-related ingredients in cosmetics, effective May 2021, leaves many details unclear, impacting companies and exports. While China aims to prevent drug misuse, the ban may hinder economic opportunities in the growing CBD market.
